From OpenAI’s Offices to a Deal With Eli Lilly — How Chai Discovery Became One of the Flashiest Names in AI Drug Development
Chai Discovery’s AI-powered platform is accelerating drug development—backed by Eli Lilly and valued at $1.3B.
Matilda
From OpenAI’s Offices to a Deal With Eli Lilly — How Chai Discovery Became One of the Flashiest Names in AI Drug Development
Chai Discovery: How an AI Startup Is Reshaping Drug Development What if artificial intelligence could cut years off the drug discovery process—and do it more accurately than traditional labs? That’s the bold promise of Chai Discovery, a fast-rising AI biotech startup that’s already secured a major partnership with pharmaceutical giant Eli Lilly and a $1.3 billion valuation less than two years after its founding. In an industry where bringing a single drug to market can take over a decade and cost billions, Chai’s approach isn’t just innovative—it may be revolutionary. Credit: Chai Discovery From OpenAI Roots to Biotech Breakthrough Chai Discovery didn’t emerge from a university lab or a legacy pharma company. Instead, its origins trace back to the heart of Silicon Valley’s AI ecosystem. Founded in 2024 by former researchers with deep experience in machine learning—including alumni from OpenAI—the startup set out to apply cutting-edge AI models to one of science’s toughest challenges: desi…
